David O. Calligaro - Concepedia

Author

David O. Calligaro

Also Known As

D Calligaro, D O Calligaro, D. Calligaro, D. O. CALLIGARO, D. O. Calligaro, D.O. Calligaro, David Calligaro, David O Calligaro, David O. Calligaro

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Novo Nordisk (Denmark)University of Maryland, Baltimore

About

David O. Calligaro is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	31	1.9K
2	Social Sciences	7	7	500
3	Natural Sciences	4	4	525
4	Health Sciences	3	3	164
5	Anesthesia	2	2	38

David O. Calligaro

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May, Robert A. Dean, Stephen L. Lowe, Journal of Neuroscience Robust Central ReductionAmyloid-β PeptideNeurochemical BiomarkersPeptide ScienceAmyloid Precursor Protein	2011	365
Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor George H. Searfoss, William H. Jordan, David O. Calligaro, Journal of Biological Chemistry	2003	336
Preclinical pharmacological profile of the selective 5-HT<sub>1F</sub>receptor agonist lasmiditan David L. Nelson, Lee A. Phebus, Kirk W. Johnson, Cephalalgia	2010	207
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans Patrick C. May, Brian A. Willis, Stephen L. Lowe, Journal of Neuroscience Amyloid βNeurodegenerative DiseasesAmyloid LoweringAlzheimer's DiseaseKey Protease	2015	195
Olanzapine: a basic science update F.P. Bymaster, Kenneth W. Perry, David L. Nelson, The British Journal of Psychiatry NeuropsychologyPsychotropic MedicationPsychopharmacologyPharmacotherapySocial Sciences	1999	149
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine Lee A. Phebus, Kirk W. Johnson, John M. Zgombick, Life Sciences NeurophysiologyMedicinePharmacologyBrain Penetration5-Ht1f Receptors	1997	139
High Affinity Stereospecific Binding of [<sup>3</sup>H] Cocaine in Striatum and its Relationship to the Dopamine Transporter David O. Calligaro, Mohyee E. Eldefrawi Membrane Biochemistry	1987	121
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. H E Shannon, Frank P. Bymaster, David O. Calligaro, Journal of Pharmacology and Experimental Therapeutics Molecular PharmacologyM1 ReceptorsMedicineG Protein-coupled ReceptorPhysiology	1994	107
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease Frank P. Bymaster, Celia A. Whitesitt, Harlan E. Shannon, Drug Development Research Neurochemical BiomarkersPharmacotherapyExperimental PharmacologyMolecular PharmacologyAlzheimer's Disease	1997	104
CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography Rebecca A. Wright, Bryan G. Johnson, Ce Zhang, Neuropharmacology Metabotropic Glutamate 2NeurophysiologyNeuroanatomyMedicineNeuropharmacology	2012	93

Page 1